Isabella Noll Sudano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1531979/publications.pdf

Version: 2024-02-01

46 papers

6,176 citations

394421 19 h-index 276875 41 g-index

47 all docs

47 docs citations

47 times ranked

8414 citing authors

#	Article	IF	CITATIONS
1	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	2.2	4,871
2	Cardiovascular disease in HIV infection. American Heart Journal, 2006, 151, 1147-1155.	2.7	172
3	Effects of Antihypertensive Drugs on Endothelial Dysfunction. Drugs, 2002, 62, 265-284.	10.9	150
4	Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease. Circulation, 2010, 122, 1789-1796.	1.6	146
5	Arterial hypertension. Lancet, The, 2021, 398, 249-261.	13.7	100
6	Retinal microvascular dysfunction in heart failure. European Heart Journal, 2018, 39, 47-56.	2.2	91
7	consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of	1.8	77
8	Cardio-Oncology (CCO), Working Group (WG) Aorta, European Journal of Preventive Cardiology, 2022, Endothelial dysfunction in cardiovascular disease and Flammer syndromeâ€"similarities and differences. EPMA Journal, 2017, 8, 99-109.	6.1	68
9	Cocoa, Blood Pressure, and Vascular Function. Frontiers in Nutrition, 2017, 4, 36.	3.7	68
10	Coffee Blunts Mental Stress–Induced Blood Pressure Increase in Habitual but Not in Nonhabitual Coffee Drinkers. Hypertension, 2005, 46, 521-526.	2.7	47
11	Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and Hypertension. Current Hypertension Reports, 2012, 14, 304-309.	3.5	40
12	Cardiovascular Effects of Coffee: Is It a Risk Factor?. Progress in Cardiovascular Nursing, 2005, 20, 65-69.	0.4	38
13	Vascular Abnormalities in Essential Hypertension. Current Pharmaceutical Design, 2011, 17, 3039-3044.	1.9	33
14	Is there a role for lifestyle changes in cardiovascular prevention? What, when and how?. Atherosclerosis Supplements, 2017, 26, 2-15.	1.2	31
15	Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 384-393.	3.0	24
16	Chronic Treatment With Long-Acting Nifedipine Reduces Vasoconstriction to Endothelin-1 in Essential Hypertension. Hypertension, 2007, 49, 285-290.	2.7	23
17	Retinal microvascular dysfunction in hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 1523-1531.e2.	1.5	22
18	Cocoa, Blood Pressure, and Vascular Function. Current Hypertension Reports, 2012, 14, 279-284.	3.5	21

#	Article	IF	CITATIONS
19	Wanagement of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European Association of Cardiovascular Imaging (EACVI), and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal	3.0	21
20	Retinal microvascular dysfunction in patients with coronary artery disease with and without heart failure: a <i>continuum</i> ?. European Journal of Heart Failure, 2019, 21, 988-997.	7.1	20
21	Polyphenols: Anti-Platelet Nutraceutical?. Current Pharmaceutical Design, 2018, 24, 146-157.	1.9	14
22	MMP-2 knockdown blunts age-dependent carotid stiffness by decreasing elastin degradation and augmenting eNOS activation. Cardiovascular Research, 2022, 118, 2385-2396.	3.8	14
23	Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Doubleâ€Blind, Randomized, Placebo ontrolled Trial. Clinical Cardiology, 2016, 39, 285-290.	1.8	8
24	Renal nerve ablation reduces blood pressure in resistant hypertension: Longâ€term clinical outcomes in a singleâ€center experience. Journal of Clinical Hypertension, 2018, 20, 627-633.	2.0	8
25	Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study. Advances in Therapy, 2022, 39, 504-517.	2.9	8
26	Agreement of PROCAM and SCORE to assess cardiovascular risk in two different low risk European populations. Preventive Medicine Reports, 2019, 13, 113-117.	1.8	7
27	Clinical benefits and safety of renal denervation in severe arterial hypertension: A longâ€ŧerm followâ€up study. Journal of Clinical Hypertension, 2020, 22, 1854-1864.	2.0	7
28	Hypovolemia and reduced hemoglobin mass in patients with heart failure and preserved ejection fraction. Physiological Reports, 2019, 7, e14222.	1.7	6
29	Potential new indications and future studies. EuroIntervention, 2013, 9, R155-R160.	3.2	6
30	Advanced carotid atherosclerosis in middle-aged subjects: comparison with PROCAM and SCORE risk categories, the potential for reclassification and cost-efficiency of carotid ultrasound in the setting of primary care. Swiss Medical Weekly, 2019, 149, w20006.	1.6	6
31	Dual blockade versus single blockade of the renin–angiotensin system in the light of ONTARGET. Journal of Hypertension, 2009, 27, S11-S14.	0.5	5
32	Prognostic value of mean pulmonary artery pressure in the stable phase after heart transplantation. European Journal of Cardio-thoracic Surgery, 2017, 52, 775-780.	1.4	5
33	Impact of local vascular lesions assessed with optical coherence tomography and ablation points on blood pressure reduction after renal denervation. Swiss Medical Weekly, 2015, 145, w14102.	1.6	4
34	Reduced adrenal stress response in patients on PCSK9 inhibitor therapy. Atherosclerosis, 2021, 325, 63-68.	0.8	3
35	Sonographic assessment of carotid atherosclerosis: preferred risk indicator for future cardiovascular events?. Swiss Medical Weekly, 2019, 149, w20142.	1.6	3
36	Is waterpipe-smoking bad for your heart?. European Heart Journal, 2018, 39, 3016-3017.	2.2	2

#	Article	IF	CITATIONS
37	Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis. ESC Heart Failure, 2022, 9, 1186-1194.	3.1	2
38	The yin and yang of light: A cardiovascular point of view. European Journal of Preventive Cardiology, 2018, 25, 1873-1874.	1.8	1
39	Ageâ€dependent impairment of the erythropoietin response to reduced central venous pressure in HFpEF patients. Physiological Reports, 2019, 7, e14021.	1.7	1
40	Effects of hemodialysis on blood volume, macro- and microvascular function. Microvascular Research, 2020, 129, 103958.	2.5	1
41	Blood Pressure-Lowering Therapy. Handbook of Experimental Pharmacology, 2020, , 1.	1.8	1
42	OUP accepted manuscript. European Journal of Preventive Cardiology, 2021, , .	1.8	1
43	Response to Letter Regarding Article, "Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis― Circulation, 2008, 118, .	1.6	O
44	Interventional therapy for hypertension: Back on track again?. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 18-25.	6.1	0
45	Reply to Letter to the Editor "Endothelial dysfunction in Takotsubo syndrome― International Journal of Cardiology, 2017, 234, 102.	1.7	O
46	Renal nerve ablation for treatment of therapy-resistant hypertension. European Heart Journal, 2013, 34, 865-8.	2.2	O